Key facts
- Transition Bio’s last known valuation is $26.8M.
- It has raised $76.5M across 3 recorded rounds; the latest was Early Stage VC ($13.3M) in Oct 2024.
- Notable investors include Bristol-Myers Squibb, Lifeforce Capital, Magnetic Ventures, Northpond Ventures, Taiho Ventures — 6 tracked in total.
- Transition Bio has filed 4 Form Ds with the SEC since 2022, most recently Oct 2024 ($13.3M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Transition Bio
Funding rounds
3 roundsAbout Transition Bio
Operator of a biotechnology company intended to build a hypothesis-free drug discovery and diagnostics platform for human health care advancement. The company harnesses droplet microfluidic approaches and protein biophysics platforms to characterize condensates with unprecedented precision, enabling medical practitioners to map condensates in molecular detail.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 27
- Website
- transitionbio.com/
- Ownership
- Privately Held (backing)
Transition Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Transition Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Transition Bio in its N-PORT filings yet. We sweep new filings monthly.